Sovereign Financial Group Inc. Lowers Holdings in Pfizer Inc. $PFE

Sovereign Financial Group Inc. decreased its stake in Pfizer Inc. (NYSE:PFE) by 8.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,197 shares of the biopharmaceutical company’s stock after selling 1,335 shares during the quarter. Sovereign Financial Group Inc.’s holdings in Pfizer were worth $344,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Concurrent Investment Advisors LLC boosted its position in Pfizer by 11.5% during the second quarter. Concurrent Investment Advisors LLC now owns 200,775 shares of the biopharmaceutical company’s stock worth $4,867,000 after purchasing an additional 20,663 shares in the last quarter. Inman Jager Wealth Management LLC boosted its position in Pfizer by 14.7% during the second quarter. Inman Jager Wealth Management LLC now owns 40,084 shares of the biopharmaceutical company’s stock worth $972,000 after purchasing an additional 5,124 shares in the last quarter. Fifth Third Wealth Advisors LLC boosted its position in Pfizer by 20.6% during the second quarter. Fifth Third Wealth Advisors LLC now owns 145,041 shares of the biopharmaceutical company’s stock worth $3,516,000 after purchasing an additional 24,756 shares in the last quarter. Richardson Financial Services Inc. boosted its position in Pfizer by 14.6% during the second quarter. Richardson Financial Services Inc. now owns 4,762 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 605 shares in the last quarter. Finally, Aberdeen Group plc boosted its position in Pfizer by 6.9% during the second quarter. Aberdeen Group plc now owns 5,272,611 shares of the biopharmaceutical company’s stock worth $128,098,000 after purchasing an additional 338,461 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $24.81 on Monday. The company has a market cap of $141.03 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The stock’s 50 day simple moving average is $24.86 and its 200-day simple moving average is $24.12. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the business posted $0.60 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Morgan Stanley lowered their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.